Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | DGKA | P23743 | 2/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.46 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.46 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.46 |
| ▸ | PRKCA | P17252 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14944797 | 0.92 | DGKA (0.57) | EPHX2DGKAALOX5PRKCEPRKCA | |
| SCHEMBL14940755 | 0.92 | DGKA (0.57) | EPHX2DGKAALOX5PRKCEPRKCA | |
| SCHEMBL14944798 | 0.86 | DGKA (0.53) | EPHX2MAPTDGKAALOX5PRKCE | |
| SCHEMBL10081238 | 0.85 | DGKA (0.54) | EPHX2ALDH1A1MAPTDGKAALOX5 | |
| SCHEMBL25298454 | 0.84 | DGKA (0.69) | MGLLFAAHALDH1A1MAPTTHRB | |
| SCHEMBL25246317 | 0.84 | DGKA (0.69) | MGLLFAAHALDH1A1MAPTTHRB | |
| SCHEMBL25298871 | 0.84 | DGKA (0.69) | MGLLFAAHALDH1A1MAPTTHRB | |
| SCHEMBL25292820 | 0.84 | DGKA (0.69) | MGLLFAAHALDH1A1MAPTTHRB | |
| SCHEMBL25291030 | 0.84 | DGKA (0.69) | MGLLFAAHALDH1A1MAPTTHRB | |
| SCHEMBL25298091 | 0.84 | DGKA (0.69) | MGLLFAAHALDH1A1MAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10821079-B2 | PKC activators and combinations thereof | COGNITIVE RESEARCH ENTERPRISES, INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-9163032-B2 | Esters of DCPLA and methods of treatment using the same | Blanchette Rockefeller Neurosciences Insitute (US) | 2015-10-20 | — | — | US | disclosed |
| US-9163032-B2 | Esters of DCPLA and methods of treatment using the same | Blanchette Rockefeller Neurosciences Insitute (US) | 2015-10-20 | — | — | US | disclosed |
| US-20140323456-A1 | ESTERS OF DCPLA AND METHODS OF TREATMENT USING THE SAME | COGNITIVE RESEARCH ENTERPRISES, INC. | 2014-10-30 | — | — | US | disclosed |
| US-20140323456-A1 | ESTERS OF DCPLA AND METHODS OF TREATMENT USING THE SAME | COGNITIVE RESEARCH ENTERPRISES, INC. | 2014-10-30 | — | — | US | disclosed |
| US-20140315990-A1 | PKC ACTIVATORS AND COMBINATIONS THEREOF | COGNITIVE RESEARCH ENTERPRISES, INC. | 2014-10-23 | — | — | US | disclosed |
| US-20140315990-A1 | PKC ACTIVATORS AND COMBINATIONS THEREOF | COGNITIVE RESEARCH ENTERPRISES, INC. | 2014-10-23 | — | — | US | disclosed |
| WO-2013071282-A1 | PKC ACTIVATORS AND COMBINATIONS THEREOF | BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE (US) | 2013-05-16 | — | — | WO | disclosed |
| WO-2013071281-A1 | ESTERS OF DCPLA AND METHODS OF TREATMENT USING THE SAME | BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE (US) | 2013-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10821079-B2 | PKC activators and combinations thereof | PRKCH, PRKCB, PRKCA | MGLL 1478/4885EPHX2 3007/4885FAAH 3868/4885 |
| US-20140323456-A1 | ESTERS OF DCPLA AND METHODS OF TREATMENT USING THE SAME | LIPA, PCCA, PNLIP | MGLL 39/4885EPHX2 721/4885FAAH 881/4885 |
| US-20140315990-A1 | PKC ACTIVATORS AND COMBINATIONS THEREOF | PRKCH, PRKCB, PRKCA | MGLL 1478/4885EPHX2 3007/4885FAAH 3868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.